If anyone is interested in tuning in to this in 15 minutes:
Qu IBD Community Advisory Panel
Meeting Agenda
June 23, 2015
5:30pm -7:00pm PDT (8:30pm - 10:00pm EDT)
Call in details
Toll free call-in number: 1.855.423.3955 (Canada/US)
Participant code: 6273948
If you require a toll free number outside of Canada/US or have any difficulties accessing the call, please contact Ms. Gigi Cheung at
[email protected].
Add this meeting to your calendar!
Download for Google calendar
Download iCal appointment
Background
In 2007, Qu Biologics was launched with a vision to develop treatments that restore health in a way compatible with our body's own healing capacities. This very different approach and vision is reflected in the innovation, passion and excitement that inspire us in our work. We are developing Site Specific Immunomodulators (SSIs). Rather than blocking or stimulating a single receptor or pathway, SSIs are designed to restore the body's normal immune response. SSIs, derived from components of killed bacteria, aim to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases, such as inflammatory bowel disease.
We are currently recruiting 60 participants for a clinical trial in Crohn's disease and expect to start a clinical trial in ulcerative colitis in a few weeks.
Previous to these clinical trials, ten patients with Crohn's disease and two patients with ulcerative colitis were treated with Qu Biologics' SSIs in a compassionate use program. Response associated with SSI treatment was as follows:
Crohn's disease
All 10 patients had a therapeutic response to SSI treatment, with improvement in symptoms
7 of 10 patients had full resolution of clinical symptoms with a course of SSI treatment of three months or more
3 patients are in sustained ongoing clinical remission after discontinuing all medication, including SSI treatment.
All 3 patients in sustained clinical remission have had a follow-up colonoscopy with confirmation of full remission.
The longest clinical remission is 4.5 years ongoing.
Ulcerative colitis
Both patients went into sustained clinical remission during SSI treatment
Both patients were able to discontinue all medications including SSI treatment
One patient remains in ongoing sustained clinical remission (2+ years), while the second patient was in remission for 17 months before having a recurrence.
Qu's IBD Community Advisory Panel was formed to help in our understanding of patient perspectives as it relates to IBD treatment and clinical trial design.
Thank you very much for joining Qu's IBD Community Advisory Panel. We sincerely appreciate your time and hope that the valuable insight we receive from you will help to make us a better patient-focused company and that we can ultimately develop and deliver relevant treatments to improve the lives of those living with IBD.
Topic: IBD Treatment Options
Today's topic will be about IBD treatment options. We are currently recruiting participants for a clinical trial in Crohn's disease and plan to begin a clinical trial in ulcerative colitis in a few weeks. Both trials involve the use of Qu's investigational treatment, QBECO SSI, which is derived from components of inactivated E. coli, and designed to stimulate an innate immune response in the GI tract and restore normal immune function. For additional information, visit
www.qucrohnstrial.com. The goal of this meeting is to help us to understand the following:
What kind of new IBD treatments are exciting to you?
In your opinion, how does QBECO SSI treatment compare with other approved and experimental treatments?
What is your experience with other IBD treatments?